Rhythm Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Rhythm Pharmaceuticals has a total shareholder equity of $61.6M and total debt of $107.4M, which brings its debt-to-equity ratio to 174.4%. Its total assets and total liabilities are $258.7M and $197.1M respectively.
Key information
174.4%
Debt to equity ratio
US$107.37m
Debt
| Interest coverage ratio | n/a |
| Cash | US$201.20m |
| Equity | US$61.58m |
| Total liabilities | US$197.07m |
| Total assets | US$258.65m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RYTM *'s short term assets ($235.8M) exceed its short term liabilities ($54.2M).
Long Term Liabilities: RYTM *'s short term assets ($235.8M) exceed its long term liabilities ($142.9M).
Debt to Equity History and Analysis
Debt Level: RYTM * has more cash than its total debt.
Reducing Debt: RYTM *'s debt to equity ratio has increased from 0% to 174.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RYTM * has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RYTM * has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.